The industry and its issues, from editor-in-chief William Looney.
 | February 1, 2012
By:William Looney
A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.
 |
 | December 1, 2011
By:William Looney
The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.
|
November 1, 2011
By:William Looney
If high prices that lower access are attributable to a flawed R&D model, can industry embrace delivering better results at lower costs.
|
 | October 1, 2011
By:William Looney
Pharm Exec celebrates its 30th birthday with a gathering of 30 of the industry's key influencers of the last three decades.
|
September 1, 2011
By:William Looney
Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.
|
August 1, 2011
By:William Looney
What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders
|
July 1, 2011
By:William Looney
More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them
|
 | June 1, 2011
By:William Looney
Now that government payers are turning to pharma to bridge budgetary shortfalls it's best to think long-term
|
 | May 1, 2011
By:William Looney
What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
